Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

AZD0120

Drug and asset intelligence for AZD0120 with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

AstraZeneca →

Mechanism of action

CAR T-cell Therapy

Recent signals(2)

CompetitiveJuly 25, 2026

AstraZeneca Initiates Phase 1b/2 Trial of AZD0120 for Relapsed/Refractory Multiple Myeloma

AstraZeneca is conducting Phase 1b/2 trial of AZD0120, a dual CAR T-cell therapy targeting CD19 and BCMA, in patients with relapsed/refractory multiple myeloma.

ClinicalJuly 18, 2026

AstraZeneca's AZD0120 Phase I Study in Multiple Myeloma Initiated

AstraZeneca has initiated Phase I study to evaluate the safety and tolerability of AZD0120 in multiple myeloma patients.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

AstraZeneca — AZD0120

July 18, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

CAR T-cell Therapy →

Hematology · Multiple Myeloma →

Multiple Myeloma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.